<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02433119</url>
  </required_header>
  <id_info>
    <org_study_id>ORT_EH_IV</org_study_id>
    <nct_id>NCT02433119</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Phase IV Clinical Trial to Compare the Efficacy and Safety of OROSARTAN® Tablet 5/160mg Versus CODIOVAN® Tablet 160/12.5mg in Patients With Essential Hypertension Uncontrolled With Valsartan 160mg Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <brief_summary>
    <textblock>
      A multi-center, randomized, double-blind, phase IV clinical trial to compare the efficacy and
      safety of OROSARTAN® tablet 5/160mg versus CODIOVAN® tablet 160/12.5mg in patients with
      essential hypertension uncontrolled with valsartan 160mg monotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2015</start_date>
  <completion_date type="Actual">September 8, 2016</completion_date>
  <primary_completion_date type="Actual">September 8, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)</measure>
    <time_frame>Baseline, Week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in MSDBP</measure>
    <time_frame>Baseline, Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Mean Sitting Systolic Blood Pressure (MSSBP)</measure>
    <time_frame>Baseline, Week 4 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Control rate in blood pressure</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Rate of patients who achieved target blood pressure(MSDBP&lt;90mmHg and MSSBP&lt;140mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder rate in blood pressure</measure>
    <time_frame>Baseline, Week 8</time_frame>
    <description>Rate of patients who achieved MSDBP≥10mmHg and MSSBP≥20mmHg decrease compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">238</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Amlodipine orotate &amp; Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amlodipine orotate 6.91mg (5mg as amlodipine) and Valsartan 160 mg, tablet, once a day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan &amp; Hydrochlorothiazide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Valsartan 160mg and Hydrochlorothiazide 12.5mg, tablet, once a day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OROSARTAN® 5/160mg</intervention_name>
    <arm_group_label>Amlodipine orotate &amp; Valsartan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CODIOVAN® 160/12.5mg</intervention_name>
    <arm_group_label>Valsartan &amp; Hydrochlorothiazide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  19 aged or over

          -  A patient who was diagnosed with essential hypertension at screening(Visit 1)

          -  A patient understood objective of this clinical trial and gave their written informed
             consent voluntarily

        Exclusion Criteria:

          -  A patient with severe hypertension(MSSBP≥200mmHg or MSDBP≥120mmHg) at Visit 1

          -  A subject with difference(as MSSBP≥20mmHg or MSDBP≥10mmHg) in blood pressure between
             right and left arm at screening evaluation

          -  Medical history or evidence of a secondary form of hypertension

          -  A subject with history of hypersensitivity to CCB(Calcium Channel Blocker),
             ARB(Angiotensin II Receptor Blocker) or sulfonamide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

